AZN.UK

11,228

-1.47%↓

HLN.UK

395.5

+0.58%↑

INDV

719.5

-2.11%↓

AZN.UK

11,228

-1.47%↓

HLN.UK

395.5

+0.58%↑

INDV

719.5

-2.11%↓

AZN.UK

11,228

-1.47%↓

HLN.UK

395.5

+0.58%↑

INDV

719.5

-2.11%↓

AZN.UK

11,228

-1.47%↓

HLN.UK

395.5

+0.58%↑

INDV

719.5

-2.11%↓

AZN.UK

11,228

-1.47%↓

HLN.UK

395.5

+0.58%↑

INDV

719.5

-2.11%↓

Search

GlaxoSmithKline PLC

Open

BrancheGesundheitswesen

1,457.5 0.07

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1448

Max

1485.5

Schlüsselkennzahlen

By Trading Economics

Einkommen

559M

501M

Verkäufe

105M

8.1B

KGV

Branchendurchschnitt

23.581

63.778

EPS

0.232

Dividendenrendite

4.3

Gewinnspanne

6.172

Angestellte

68,629

EBITDA

-52M

1.1B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+11.15% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.30%

2.39%

Nächstes Ergebnis

30. Apr. 2025

Nächste Dividendenausschüttung

10. Apr. 2025

Nächstes Ex-Dividendendatum

15. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-586M

59B

Vorheriger Eröffnungskurs

1457.43

Vorheriger Schlusskurs

1457.5

Nachrichtenstimmung

By Acuity

52%

48%

319 / 386 Ranking in Healthcare

GlaxoSmithKline PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Feb. 2025, 11:32 UTC

Ergebnisse

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5. Feb. 2025, 08:56 UTC

Ergebnisse

Correction to GSK Article

5. Feb. 2025, 08:24 UTC

Ergebnisse

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5. Feb. 2025, 07:43 UTC

Ergebnisse

GSK Expects Further Profit Growth After Beating Market Views

3. Apr. 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. Apr. 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3. Apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26. März 2025, 22:29 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26. März 2025, 19:19 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26. März 2025, 17:39 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19. März 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17. März 2025, 09:00 UTC

Top News

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24. Feb. 2025, 07:05 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Completes Acquisition of IDRx

14. Feb. 2025, 11:38 UTC

Top News
Ergebnisse

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14. Feb. 2025, 11:30 UTC

Top News
Ergebnisse

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5. Feb. 2025, 15:33 UTC

Market Talk
Ergebnisse

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5. Feb. 2025, 08:38 UTC

Market Talk
Ergebnisse

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5. Feb. 2025, 07:05 UTC

Ergebnisse

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5. Feb. 2025, 07:04 UTC

Ergebnisse

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5. Feb. 2025, 07:03 UTC

Ergebnisse

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5. Feb. 2025, 07:03 UTC

Ergebnisse

GSK PLC Raises Mid-Term View

5. Feb. 2025, 07:03 UTC

Ergebnisse

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5. Feb. 2025, 07:02 UTC

Ergebnisse

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5. Feb. 2025, 07:02 UTC

Ergebnisse

GSK PLC Issues GBP2B Buyback

5. Feb. 2025, 07:01 UTC

Ergebnisse

GSK PLC Declares 4Q Dividend of 16p

5. Feb. 2025, 07:00 UTC

Ergebnisse

GSK PLC 4Q Core EPS Consensus Was 20.6p

5. Feb. 2025, 07:00 UTC

Ergebnisse

GSK PLC 4Q Sales Consensus Was GBP7.83B

5. Feb. 2025, 07:00 UTC

Ergebnisse

GSK PLC 4Q Pretax Pft GBP563M

5. Feb. 2025, 07:00 UTC

Ergebnisse

GSK PLC 4Q EPS 10.0p

Peer-Vergleich

Kursveränderung

GlaxoSmithKline PLC Prognose

Kursziel

By TipRanks

11.15% Vorteil

12-Monats-Prognose

Durchschnitt 1,593.33 GBX  11.15%

Hoch 2,290 GBX

Tief 1,450 GBX

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für GlaxoSmithKline PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

2

Buy

8

Halten

2

Sell

Stimmung

By Acuity

319 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.